{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:12:49Z","timestamp":1778083969482,"version":"3.51.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Due to the unpredictable exposure of linezolid with a standard dosing regimen, therapeutic drug monitoring (TDM) has been recommended to guide it despite limited evidence on clinical endpoints. The primary objective was to determine whether achieving therapeutic linezolid concentrations at the first TDM measurement is associated with clinical cure. Microbiological eradication and 7 day and 30 day mortality were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study in a cohort of patients with confirmed Gram-positive (Enterococcus\/Staphylococcus spp.) infections and undergoing TDM. A steady-state linezolid trough concentration (Cmin,ss) of 2\u20138\u2005mg\/L was considered therapeutic. A multivariable logistic regression model assessed predictive factors associated with clinical cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four hundred patients (median age 68\u2005years, 66.5% male) were included. Infections were mainly intra-abdominal (29.3%), skin\/soft tissue or bone\/joint (25.5%) and respiratory (21%). At first measurement only 34% of patients reached the therapeutic range, with 34.5% below range and 31.5% above range. Clinical cure rate was 76.3% and 30 day all-cause mortality was 20%. Multivariable logistic regression showed that achieving therapeutic Cmin,ss significantly increased the likelihood of clinical cure (OR 1.78, 95% CI 1.02\u20133.19). Conversely, a higher Charlson index, liver cirrhosis and sepsis\/septic shock requiring ICU admission were risk factors for failure. Other clinical outcomes were not independently related to Cmin,ss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that achieving early therapeutic linezolid concentrations is associated with a higher likelihood of clinical cure and highlights the limitations of an initial standard dosing. In this scenario, an early TDM may help to identify patients out-of-range who need guided dosing to ensure the achievement of pharmacokinetic\/pharmacodynamic targets. Further prospective studies are needed to assess the impact of TDM on survival, microbiological outcomes and cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag137","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:44:39Z","timestamp":1775648679000},"source":"Crossref","is-referenced-by-count":0,"title":["Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring"],"prefix":"10.1093","volume":"81","author":[{"given":"Daniel","family":"Fres\u00e1n","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra , Pamplona ,","place":["Spain"]},{"name":"PK\/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Sorl\u00ed","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III , Av. de Monforte de Lemos, 5, Madrid 28029 ,","place":["Spain"]},{"name":"Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Barcel\u00f3-Vidal","sequence":"additional","affiliation":[{"name":"Medicines Area and Pharmacy Service, Barcelona Territorial Management, Institut Catal\u00e0 de la Salut , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Rodrigo-Moreno","sequence":"additional","affiliation":[{"name":"Laboratori de Referencia de Catalunya , El Prat de Llobegrat, Barcelona 08820 ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosana","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Intensive Care Department, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pilar","family":"Gracia","sequence":"additional","affiliation":[{"name":"Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra , Barcelona ,","place":["Spain"]},{"name":"Intensive Care Department, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]},{"name":"GREPAC (Critical Illness Research Group), Hospital del Mar Research Institute (IMIM) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Subirana","sequence":"additional","affiliation":[{"name":"CIBER Center for Cardiovascular Diseases (CIBERCV) , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]},{"name":"Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Surgical Intensive Care, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Cerro","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Surgical Intensive Care, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Surgical Intensive Care, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Roberts","sequence":"additional","affiliation":[{"name":"PK\/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Basel ,","place":["Switzerland"]},{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane ,","place":["Australia"]},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane ,","place":["Australia"]},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital , Brisbane ,","place":["Australia"]},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier , N\u00eemes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Juanes","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4794-5936","authenticated-orcid":false,"given":"Adela","family":"Ben\u00edtez-Cano","sequence":"additional","affiliation":[{"name":"PK\/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Basel ,","place":["Switzerland"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Department of Anaesthesiology and Surgical Intensive Care, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3215-320X","authenticated-orcid":false,"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[{"name":"PK\/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Basel ,","place":["Switzerland"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III , Av. de Monforte de Lemos, 5, Madrid 28029 ,","place":["Spain"]},{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026050611255465000_dkag137-B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit"},{"key":"2026050611255465000_dkag137-B2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1128\/AAC.50.4.1599-1602.2006","article-title":"Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients","volume":"50","author":"Bishop","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050611255465000_dkag137-B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jointm.2022.05.006","article-title":"Clinical efficacy and safety of linezolid in intensive care unit patients","volume":"3","author":"Ma","year":"2023","journal-title":"J Intensive Med"},{"key":"2026050611255465000_dkag137-B4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.farma.2011.04.001","article-title":"Effectiveness and use of linezolid in hospitalisation wards","volume":"35","author":"Rivas","year":"2011","journal-title":"Farm Hosp"},{"key":"2026050611255465000_dkag137-B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08831-7","article-title":"Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2026050611255465000_dkag137-B6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/cid\/ciac917","article-title":"Linezolid population pharmacokinetics to improve dosing in cardiosurgical patients: factoring a new drug\u2013drug interaction pathway","volume":"76","author":"Pai","year":"2023","journal-title":"Clin Infec Dis"},{"key":"2026050611255465000_dkag137-B7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026050611255465000_dkag137-B8","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"},{"key":"2026050611255465000_dkag137-B9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026050611255465000_dkag137-B10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.anpede.2024.05.001","article-title":"Therapeutic drug monitoring of antibiotic and antifungical drugs in paediatric and newborn patients. Consensus guidelines of the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Paediatric Infectious Diseases (SEIP)","volume":"101","author":"Luque","year":"2024","journal-title":"An Pediatr (Engl Ed)"},{"key":"2026050611255465000_dkag137-B11","author":"Gu\u00eda PRIOAM"},{"key":"2026050611255465000_dkag137-B12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/atm.2020.03.207","article-title":"Does the conventional dosage of linezolid necessitate therapeutic drug monitoring? Experience from a prospective observational study","volume":"8","author":"Fang","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026050611255465000_dkag137-B13","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026050611255465000_dkag137-B14","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026050611255465000_dkag137-B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106783","article-title":"LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring","volume":"61","author":"Lau","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026050611255465000_dkag137-B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1310309","article-title":"Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers","volume":"15","author":"Thirot","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026050611255465000_dkag137-B17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2026050611255465000_dkag137-B18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bcp.12806","article-title":"A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?","volume":"81","author":"Pea","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2026050611255465000_dkag137-B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-17","article-title":"Systematic therapeutic drug monitoring for linezolid: variability and clinical impact","volume":"61","author":"Galar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050611255465000_dkag137-B20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00228-022-03340-z","article-title":"Applying pharmacokinetic\/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence","volume":"78","author":"El-Gaml","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026050611255465000_dkag137-B21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026050611255465000_dkag137-B22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2026050611255465000_dkag137-B23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF00273563","article-title":"Validation of a severity of illness score (APACHE II) in a surgical intensive care unit","volume":"15","author":"Giangiuliani","year":"1989","journal-title":"Intensive Care Med"},{"key":"2026050611255465000_dkag137-B24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026050611255465000_dkag137-B25","volume-title":"StatPearls","author":"Tsoris","year":"2025"},{"key":"2026050611255465000_dkag137-B26","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026050611255465000_dkag137-B27","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050611255465000_dkag137-B28","author":"EUCAST"},{"key":"2026050611255465000_dkag137-B29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s13063-019-3437-x","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin\/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial","volume":"20","author":"Hagel","year":"2019","journal-title":"Trials"},{"key":"2026050611255465000_dkag137-B30","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"key":"2026050611255465000_dkag137-B31","author":"European Medicines Agency"},{"key":"2026050611255465000_dkag137-B32","author":"Blanche"},{"key":"2026050611255465000_dkag137-B33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/1120009X.2024.2440192","article-title":"Optimizing the dosing regimens of linezolid against gram-positive cocci in critically ill patients with different renal functions: a Monte Carlo simulation","volume":"37","author":"Qiu","year":"2025","journal-title":"J Chemother"},{"key":"2026050611255465000_dkag137-B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.844567","article-title":"Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026050611255465000_dkag137-B35","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13100961","article-title":"Linezolid pharmacokinetics in critically ill patients: continuous versus intermittent infusion","volume":"13","author":"Bodolea","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2026050611255465000_dkag137-B36","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030296","article-title":"Continuous versus intermittent linezolid infusion for critically ill patients with hospital-acquired and ventilator-associated pneumonia: efficacy and safety challenges","volume":"15","author":"Abou Warda","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026050611255465000_dkag137-B37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ijid.2020.02.044","article-title":"Impact of augmented renal clearance on the pharmacokinetics of linezolid: advantages of continuous infusion from a pharmacokinetic\/pharmacodynamic perspective","volume":"93","author":"Barrasa","year":"2020","journal-title":"Int J Infec Dis"},{"key":"2026050611255465000_dkag137-B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107661","article-title":"An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring","volume":"67","author":"Fres\u00e1n","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"2026050611255465000_dkag137-B39","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-021-00479-w","article-title":"Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients","volume":"22","author":"Kawasuji","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026050611255465000_dkag137-B40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijid.2023.01.035","article-title":"Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection","volume":"129","author":"Huang","year":"2023","journal-title":"Int J Infec Dis"},{"key":"2026050611255465000_dkag137-B41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag137\/68229985\/dkag137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag137\/68229985\/dkag137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:25:57Z","timestamp":1778081157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag137\/8671047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag137","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag137"}}